Page last updated: 2024-11-12

sch 51866

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SCH 51866: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15473392
CHEMBL ID1628659
SCHEMBL ID437200
MeSH IDM0253915

Synonyms (15)

Synonym
sch-51866
CHEMBL1628659 ,
sch 51866
cis-5,6a,7,8,9,9a-hexahydro-2-(4-(trifluoromethyl)phenylmethyl)-5-methyl-cyclopent(4,5)imidazo(2,1-b)purin-4(3h)-one
(11r,15s)-8-methyl-4-{[4-(trifluoromethyl)phenyl]methyl}-1,3,5,8,10-pentaazatetracyclo[7.6.0.0^{2,6}.0^{11,15}]pentadeca-2(6),3,9-trien-7-one
gtpl5270
cyclopent(4,5)imidazo(2,1-b)purin-4(1h)-one, 5,6a,7,8,9,9a-hexahydro-5-methyl-2-((4-(trifluoromethyl)phenyl)methyl)-, (6ar,9as)-rel-
167298-74-0
unii-f8gu4psp29
f8gu4psp29 ,
SCHEMBL437200
bdbm50237791
(6ar,9as)-5-methyl-2-(4-(trifluoromethyl)benzyl)-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(1h)-one
Q15634078
(11r,15s)-8-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one

Research Excerpts

Overview

SCH 51866 is a potent and selective PDE1 and PDE5 inhibitor.

ExcerptReferenceRelevance
"SCH 51866 is a potent and selective PDE1 and PDE5 inhibitor. "( Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Ahn, HS; Chatterjee, M; Chintala, M; Chiu, P; Davis, H; Fawzi, A; Lin, CC; Sybertz, EJ; Tulshian, D; Vemulapalli, S; Watkins, RW, 1996
)
2

Bioavailability

ExcerptReferenceRelevance
" 6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one was identified as an orally bioavailable and brain penetrating PDE1B enzyme inhibitor with potent memory-enhancing effects in a rat model of object recognition memory."( Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.
Aertgeerts, K; Allerston, CK; Andersen, CB; Augustin, M; Barido, R; Barker, R; Botrous, I; Branstetter, B; Breitenbucher, JG; Cedervall, EP; Chun, LE; Dyck, B; Edwards, TE; Gharbaoui, T; Gomez, L; Hudson, AR; Lee, D; Limberis, J; Marrone, T; Massari, ME; Neul, D; Peters, M; Petroski, R; Schmelzer, K; Sebring, K; Sridhar, V; Tabatabaei, A; Xu, R; Zhou, X, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)0.06000.00001.18439.6140AID1443922
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1345204Human phosphodiesterase 7B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2000Biochemical and biophysical research communications, May-19, Volume: 271, Issue:3
Identification of human PDE7B, a cAMP-specific phosphodiesterase.
AID1345264Human phosphodiesterase 5A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1996Journal of cardiovascular pharmacology, Dec, Volume: 28, Issue:6
Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
AID1443922Inhibition of PDE5 (unknown origin)2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.
AID1443921Inhibition of PDE1 (unknown origin)2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's3 (42.86)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]